Every article, report, and earnings note where BSX appears.
Boston Scientific posted solid Q2 2026 growth, but lowered full-year guidance as WATCHMAN and U.S. EP slowed. The stock looks more reasonable after the reset, with durable pipeline optionality and a Buy rating.
Three insiders bought $9.29 million of BSX shares in roughly two weeks, including a roughly $9 million purchase by CEO Michael Mahoney. That confidence signal lands alongside 19.9% revenue growth, 55.6% EPS growth and a valuation that already reflects a reset.
The setbacks at Intuitive Surgical and HCA expose real pressure in elective procedures, but the evidence points more to coverage and payer mix than a broad healthcare demand collapse. UnitedHealth's guidance increase and Intuitive's maintained procedure outlook show why investors should separate marginal-patient exposure from underlying utilization.
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
Boston Scientific Corporation (BSX) falls sharply after management flagged declining standalone Watchman procedures and near-term competitive pressure. Despite strong recent earnings, the market is repricing growth expectations, sending shares lower on heavy volume as investors reassess the stock’s premium valuation.
No, Neuralink is not publicly traded. Retail investors can’t buy it in a normal brokerage account today, so the realistic alternatives are waiting for an IPO, looking at comparable public medical-device stocks, or—if accredited—private secondary markets.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate BSX ReportCancel anytime